FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065407464> ?p ?o ?g. }

• W2065407464 endingPage "e26" @default.
• W2065407464 startingPage "e19" @default.
• W2065407464 abstract "Background The purpose of this study was to determine the prevalence of MET amplification and mutation among GU malignancies and its association with clinical factors and responses to c-MET inhibitors. Patients and Methods Patients with GU malignancies referred to our Phase I Clinical Trials Program were evaluated for MET mutation and amplification and outcomes using protocols with c-MET inhibitors. Results MET amplification was found in 7 of 97 (7.2%) patients (4/27 renal [all clear cell], 1/18 urothelial, and 2/12 adrenocortical carcinoma), with MET mutation/variant in 3 of 54 (5.6%) (2/20 renal cell carcinoma [RCC] [1 clear cell and 1 papillary] and 1/16 prostate cancer). No demographic characteristics were associated with specific MET abnormalities, but patients who tested positive for mutation or amplification had more metastatic sites (median, 4 vs. 3 for wild type MET). Median overall survival after phase I consultation was 6.1 and 11.5 months for patients with and without a MET alteration, respectively (hazard ratio, 2.8; 95% confidence interval, 1.1 to 6.9; P = .034). Twenty-nine (25%) patients were treated according to a c-MET inhibitor protocol. Six (21%) had a partial response (prostate and RCC) and 10 (34%) had stable disease as best response. Median time to tumor progression was 2.3 months (range, 0.4-19.7) for all treated patients with no responses in patients with a MET abnormality or single-agent c-MET inhibitor treatment. Conclusion MET genetic abnormalities occur in diverse GU malignancies and are associated with a worse prognosis in a phase I setting. Efficacy of c-MET inhibitors was more pronounced in patients without MET abnormalities and when combined with other targets/drugs." @default.
• W2065407464 created "2016-06-24" @default.
• W2065407464 creator A5005194857 @default.
• W2065407464 creator A5017162434 @default.
• W2065407464 creator A5021572863 @default.
• W2065407464 creator A5023657068 @default.
• W2065407464 creator A5026095888 @default.
• W2065407464 creator A5036211173 @default.
• W2065407464 creator A5043675371 @default.
• W2065407464 creator A5045197829 @default.
• W2065407464 creator A5046992109 @default.
• W2065407464 creator A5053481267 @default.
• W2065407464 creator A5058115259 @default.
• W2065407464 creator A5061237827 @default.
• W2065407464 creator A5062740919 @default.
• W2065407464 creator A5064252296 @default.
• W2065407464 creator A5069777765 @default.
• W2065407464 creator A5071800834 @default.
• W2065407464 creator A5076426660 @default.
• W2065407464 date "2015-02-01" @default.
• W2065407464 modified "2023-10-18" @default.
• W2065407464 title "MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors" @default.
• W2065407464 cites W1994912526 @default.
• W2065407464 cites W2003463361 @default.
• W2065407464 cites W2019367792 @default.
• W2065407464 cites W2019573100 @default.
• W2065407464 cites W2019607817 @default.
• W2065407464 cites W2042919832 @default.
• W2065407464 cites W2047625444 @default.
• W2065407464 cites W2054042846 @default.
• W2065407464 cites W2062110561 @default.
• W2065407464 cites W2074904551 @default.
• W2065407464 cites W2081781537 @default.
• W2065407464 cites W2094337993 @default.
• W2065407464 cites W2094556354 @default.
• W2065407464 cites W2100322919 @default.
• W2065407464 cites W2106582614 @default.
• W2065407464 cites W2116095691 @default.
• W2065407464 cites W2127401934 @default.
• W2065407464 cites W2132051411 @default.
• W2065407464 cites W2139248078 @default.
• W2065407464 cites W2149152070 @default.
• W2065407464 cites W2152255534 @default.
• W2065407464 cites W2158424267 @default.
• W2065407464 cites W2168825275 @default.
• W2065407464 cites W2169614462 @default.
• W2065407464 cites W4245967957 @default.
• W2065407464 doi "https://doi.org/10.1016/j.clgc.2014.06.017" @default.
• W2065407464 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5144738" @default.
• W2065407464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25087088" @default.
• W2065407464 hasPublicationYear "2015" @default.
• W2065407464 type Work @default.
• W2065407464 sameAs 2065407464 @default.
• W2065407464 citedByCount "17" @default.
• W2065407464 countsByYear W20654074642015 @default.
• W2065407464 countsByYear W20654074642016 @default.
• W2065407464 countsByYear W20654074642017 @default.
• W2065407464 countsByYear W20654074642018 @default.
• W2065407464 countsByYear W20654074642019 @default.
• W2065407464 countsByYear W20654074642020 @default.
• W2065407464 countsByYear W20654074642022 @default.
• W2065407464 countsByYear W20654074642023 @default.
• W2065407464 crossrefType "journal-article" @default.
• W2065407464 hasAuthorship W2065407464A5005194857 @default.
• W2065407464 hasAuthorship W2065407464A5017162434 @default.
• W2065407464 hasAuthorship W2065407464A5021572863 @default.
• W2065407464 hasAuthorship W2065407464A5023657068 @default.
• W2065407464 hasAuthorship W2065407464A5026095888 @default.
• W2065407464 hasAuthorship W2065407464A5036211173 @default.
• W2065407464 hasAuthorship W2065407464A5043675371 @default.
• W2065407464 hasAuthorship W2065407464A5045197829 @default.
• W2065407464 hasAuthorship W2065407464A5046992109 @default.
• W2065407464 hasAuthorship W2065407464A5053481267 @default.
• W2065407464 hasAuthorship W2065407464A5058115259 @default.
• W2065407464 hasAuthorship W2065407464A5061237827 @default.
• W2065407464 hasAuthorship W2065407464A5062740919 @default.
• W2065407464 hasAuthorship W2065407464A5064252296 @default.
• W2065407464 hasAuthorship W2065407464A5069777765 @default.
• W2065407464 hasAuthorship W2065407464A5071800834 @default.
• W2065407464 hasAuthorship W2065407464A5076426660 @default.
• W2065407464 hasBestOaLocation W20654074642 @default.
• W2065407464 hasConcept C121608353 @default.
• W2065407464 hasConcept C126322002 @default.
• W2065407464 hasConcept C133507102 @default.
• W2065407464 hasConcept C143998085 @default.
• W2065407464 hasConcept C207103383 @default.
• W2065407464 hasConcept C2777472916 @default.
• W2065407464 hasConcept C44249647 @default.
• W2065407464 hasConcept C71924100 @default.
• W2065407464 hasConcept C90924648 @default.
• W2065407464 hasConceptScore W2065407464C121608353 @default.
• W2065407464 hasConceptScore W2065407464C126322002 @default.
• W2065407464 hasConceptScore W2065407464C133507102 @default.
• W2065407464 hasConceptScore W2065407464C143998085 @default.
• W2065407464 hasConceptScore W2065407464C207103383 @default.
• W2065407464 hasConceptScore W2065407464C2777472916 @default.
• W2065407464 hasConceptScore W2065407464C44249647 @default.
• W2065407464 hasConceptScore W2065407464C71924100 @default.

• next